Omid Hamid on Vigilance with Toxicities from Combination Immunotherapies

Video

Dr. Omid Hamid discusses some toxicities that come from combination immunotherapies

Omid Hamid, MD, chief of Translational Research and Immunotherapy of The Angeles Clinic, discusses some toxicities that come from combination immunotherapies, such as type 1 diabetes and hypoadrenalism.

Despite the ease with which these adverse events can usually be remedied, Hamid urges clinicians to carefully consider a patient’s complaints. If these toxicities are caught early enough, they are less complicated to deal with.

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a man wearing scrubs in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with blonde hair wearing a denim jacket in front of a blue background
2 experts are featured in this series.
2 experts are featured in this series.
Photo of a woman with brown hair and a floral blouse
Photo of a woman with a blue border around the image
Related Content
doctor in white coat holding hand out with the word "immunotherapy" floating above

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers

Russ Conroy
November 12th 2024
Article

Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.

Ask The Right Questions: Clinical Pearls of AE Management

Ask The Right Questions: Clinical Pearls of AE Management

Lindsay Fischer
February 15th 2022
Podcast

In this episode of “The Vitals,” Mark Honor, PA-C, discusses adverse event management in patients receiving different therapeutic options.

kidney cancer

Atezolizumab Falls Short in Pretreated, Advanced Renal Cell Carcinoma

Gina Mauro
June 17th 2023
Article

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Immunotherapy in the Age of COVID-19

Immunotherapy in the Age of COVID-19

Brielle Benyon
August 15th 2020
Podcast

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS

Lindsay Fischer
June 3rd 2023
Article

Tremelimumab plus durvalumab (STRIDE) showed a manageable immune-related adverse event profile in the phase 3 HIMALAYA trial.

FDA

Trifluridine/Tipiracil, Plus Bevacizumab Under Priority Review for Refractory mCRC

Kristi Rosa
April 24th 2023
Article

Trifluridine plus tipiracil, with or without bevacizumab, has been granted priority review status for the treatment of refractory, metastatic colorectal cancer.